about
The in vivo TRPV6 protein starts at a non-AUG triplet, decoded as methionine, upstream of canonical initiation at AUGRole of gas chromatography-mass spectrometry with negative ion chemical ionization in clinical and forensic toxicology, doping control, and biomonitoringToxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay, and gas chromatography-mass spectrometryMetabolism of designer drugs of abuseBeta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometryStudies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MSToxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy')Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.Simultaneous LC-MS/MS determination of JWH-210, RCS-4, ∆(9)-tetrahydrocannabinol, and their main metabolites in pig and human serum, whole blood, and urine for comparing pharmacokinetic data.Development of the first metabolite-based LC-MS(n) urine drug screening procedure-exemplified for antidepressants.Negative ion chemical ionization gas chromatography-mass spectrometry and atmospheric pressure chemical ionization liquid chromatography-mass spectrometry of low-dosed and/or polar drugs in plasma.Metabolism and toxicological detection of the new designer drug 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry.Metabolism and toxicological detection of the new designer drug 4'-methoxy-alpha-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry.Hyphenated mass spectrometric techniques-indispensable tools in clinical and forensic toxicology and in doping control.Systematic comparison of bias and precision data obtained with multiple-point and one-point calibration in six validated multianalyte assays for quantification of drugs in human plasma.Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry.Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy.Systematic investigation of ion suppression and enhancement effects of fourteen stable-isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multIon suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultra-high-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray iThe breast feeding mother and xenon anaesthesia: four case reports. Breast feeding and xenon anaesthesiaAutomated mass spectral deconvolution and identification system for GC-MS screening for drugs, poisons, and metabolites in urine.Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.Screening procedures for simultaneous detection of several drug classes used for high throughput toxicological analyses and doping control. A review.Towards a universal LC-MS screening procedure - can an LIT LC-MS(n) screening approach and reference library be used on a quadrupole-LIT hybrid instrument?Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa)Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.2-methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques.The in vivo and in vitro metabolism and the detectability in urine of 3',4'-methylenedioxy-alpha-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS(n.).Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC-MS, LC-MSn, and LC-HR-MSn.New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry.Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography-mass spectrometry.Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MS(n) techniques.Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MS(n), and LC-high resolution-MS/MS.Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps.Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP).Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn , and LC-HR-MSn.
P50
Q24338946-9C8374CC-A640-40D3-9D60-E74FBA410454Q28192554-AD7B23F0-C2B5-40D8-818F-541D56995399Q28206268-60DE244D-8786-476A-B36E-0071AC98866FQ28258085-8A450FB6-6DBC-469A-A418-5ED80751B81CQ28277604-56486E7E-4847-4B96-B4AE-3D2F7F3E20EDQ28297761-4ECC44E7-A1F9-44FC-9560-D5FCD9024FE4Q28373367-6B1C4977-B30F-4880-A09D-24B94F706106Q30679989-973D9E7E-F513-4F84-A7DD-CD8C645F7C95Q30724754-6E66233C-DC05-4B62-946C-FE681C815EFEQ30910292-AE123B47-0BA3-4774-9E2C-36B0821602DDQ30992027-FDF84FF5-E901-4C34-8CD6-E6BBC69070D0Q31035975-5EA71B2E-7FBB-4463-80F5-73B54B8263E5Q31153032-D7F7592E-0691-4945-A5BD-A5591FF64BD1Q33188077-8477D90B-AFCA-4891-B712-12AA2CAA3D8AQ33260868-C35CA519-CF2F-44DA-923F-03B15FECD53FQ33285388-5B681BB8-44F6-4004-AAC5-B7F3EB02D94CQ33425476-B90BDB87-9D20-400D-B5A4-6DC956D37E11Q33430638-6D76C1FE-2B75-41E5-A9EA-370F83373024Q33445373-5F64A782-8951-42AF-A281-89877372733CQ33448131-A211D211-EBDC-4F9D-9DFA-7B5807352E46Q33532311-0640640A-1D91-4099-A32D-094539C9E3F7Q33534587-20B4E671-A12D-4A2F-9852-257FB0BC3D84Q34014766-6AD81E98-9EC4-4AC4-9EE0-03E671C2B86BQ34106439-B9006786-93B5-4134-A3B0-5B2C14FD4F38Q34142688-CE7EA923-844A-4930-9233-5CF8F25EECDFQ34165511-F0C9B439-B81C-4E47-9786-5F90D8099268Q34181061-7FC362EB-299A-4363-926A-43ABC42629DBQ34214861-124EDB0F-3033-4BA7-84E4-C56CE390BDD2Q34325128-1ADDFD48-A565-462C-9570-319DCE61BD1AQ34377572-32902AAB-2DA7-4207-BE64-C20F91A2220CQ34378886-32AF92A1-99EC-4EFA-96EE-82B4B80B80D7Q34436648-C970067C-92E0-42FF-B549-65F689A681D0Q34437288-47377212-D203-4F22-BB59-60CDF3F63CF2Q34451894-8029469A-75E7-4DA6-A6D8-02439C6B4C34Q34457560-167FB2C4-6C49-408F-889A-5586480E4BE0Q34489642-CF1C85A2-AEC0-4A18-B909-8C8D345D1B58Q34490537-9D5C1E9F-6FDE-470D-A6A6-DCD9EB5B1173Q34497670-6D45B32F-CBAE-4980-AFFC-03367D4B5346Q34502785-5EF2467F-4EAB-411D-A83E-0207CEB69D81Q34510789-41C26C06-B606-4381-9947-F33D5EBA039C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Hans H Maurer
@nl
Hans H Maurer
@sl
Hans H. Maurer
@en
Hans H. Maurer
@es
هانس إتش. مورير
@ar
type
label
Hans H Maurer
@nl
Hans H Maurer
@sl
Hans H. Maurer
@en
Hans H. Maurer
@es
هانس إتش. مورير
@ar
prefLabel
Hans H Maurer
@nl
Hans H Maurer
@sl
Hans H. Maurer
@en
Hans H. Maurer
@es
هانس إتش. مورير
@ar
P1006
P214
P244
P1006
P106
P1153
7201617988
P21
P214
P244
P31
P3835
hans-maurer
P496
0000-0003-4579-4660
P569
1950-01-01T00:00:00Z
P734
P735
P7859
lccn-n85085652